A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Astellas Pharma Inc
Astellas Pharma Inc
CEBIOTEX
Novartis
Novartis
SN BioScience
MOMA Therapeutics
EMD Serono
Toray Industries, Inc
Actuate Therapeutics Inc.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Txinno Bioscience Inc.
IGM Biosciences, Inc.
Ono Pharmaceutical Co. Ltd
Merck Sharp & Dohme LLC
Ono Pharmaceutical Co. Ltd
EpicentRx, Inc.
Taiho Oncology, Inc.
Symphogen A/S
Bayer
Sumitomo Pharma America, Inc.
Eisai Inc.
AstraZeneca
EpicentRx, Inc.
Boehringer Ingelheim
Sumitomo Pharma Co., Ltd.
Athenex, Inc.
Shanghai JMT-Bio Inc.
Intezyne Technologies, Inc.
Novartis
Gilead Sciences
Eli Lilly and Company
EMD Serono
Takeda
Bristol-Myers Squibb
mAbxience Research S.L.
Oncolytics Biotech
Oncolytics Biotech
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
SuZhou Stainwei Biotech Inc.
Merrimack Pharmaceuticals
GlaxoSmithKline
AbbVie
Traws Pharma, Inc.
Genentech, Inc.
Genentech, Inc.
Merrimack Pharmaceuticals